- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Can They Turn the Tide
U.S. Pharmaceuticals & Biotech Can They Turn the Tide
UPDATED Mar 09, 2024
Annually loss-making mid-caps and large-caps with sound financial health.
68 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| AXSMAxsome Therapeutics | US$73.92 | -10.3% | 26.6% | US$3.5b | US$120.53 | PS12.9x | E60.3% | n/a | ||
| ACADACADIA Pharmaceuticals | US$23.44 | -2.4% | 15.1% | US$3.9b | US$33.50 | PS5.3x | E46.0% | n/a | ||
| ITCIIntra-Cellular Therapies | US$67.48 | -5.6% | 53.4% | US$6.5b | US$83.10 | PS14.1x | E56.6% | n/a | ||
| EXASExact Sciences | US$60.04 | 1.0% | -3.1% | US$10.9b | US$88.49 | PS4.4x | E61.5% | n/a | ||
| BIOBio-Rad Laboratories | US$343.76 | 3.4% | -28.1% | US$9.7b | US$435.73 | PS3.7x | E81.3% | n/a | ||
| PRVBProvention Bio | US$24.98 | 2.7% | 456.3% | US$2.4b | US$24.00 | PS183.6x | E75.7% | n/a | ||
| MDGLMadrigal Pharmaceuticals | US$255.32 | 1.5% | 5.7% | US$5.1b | US$323.92 | PB12.5x | E62.6% | n/a | ||
| IOVAIovance Biotherapeutics | US$15.70 | -6.5% | 152.8% | US$4.4b | US$25.92 | PS3688.1x | E60.8% | n/a | ||
| VCELVericel | US$45.20 | 1.1% | 53.7% | US$2.2b | US$52.07 | PS11.1x | E49.4% | n/a | ||
| BGNEBeiGene | US$158.52 | -3.9% | -26.7% | US$16.6b | US$270.32 | PS6.7x | E57.4% | n/a | ||
| RETAReata Pharmaceuticals | US$172.36 | 0.09% | 581.8% | US$6.6b | US$172.44 | PS279.7x | E62.0% | n/a | ||
| IMCRImmunocore Holdings | US$61.61 | -8.6% | 19.9% | US$3.1b | US$84.78 | PS12.3x | E29.3% | n/a | ||
| RAREUltragenyx Pharmaceutical | US$50.53 | -5.9% | 30.4% | US$4.2b | US$89.85 | PS9.6x | E48.2% | n/a | ||
| LEGNLegend Biotech | US$63.25 | -3.5% | 45.7% | US$11.5b | US$86.02 | PS49.3x | E58.1% | n/a | ||
| ISEEIVERIC bio | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | ||
| SRPTSarepta Therapeutics | US$124.37 | -3.3% | -13.6% | US$11.7b | US$164.42 | PS9.4x | E41.8% | n/a | ||
| RCKTRocket Pharmaceuticals | US$27.87 | -8.7% | 51.0% | US$2.5b | US$51.25 | PB5.1x | E54.1% | n/a | ||
| KRTXKaruna Therapeutics | US$319.95 | 1.2% | 78.7% | US$12.2b | US$327.14 | PS18662.6x | E60.7% | n/a | ||
| SGENSeagen | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | ||
| BPMCBlueprint Medicines | US$92.30 | -3.0% | 119.8% | US$5.7b | US$97.18 | PS22.7x | E66.3% | n/a | ||
| KROSKeros Therapeutics | US$70.48 | 2.4% | 59.2% | US$2.5b | US$85.30 | PS16795.1x | E11.6% | n/a | ||
| MRNAModerna | US$103.03 | 8.4% | -25.5% | US$39.4b | US$133.77 | PS5.7x | E58.0% | n/a | ||
| OLKOlink Holding | US$23.65 | 2.8% | 8.5% | US$2.9b | US$26.00 | PS18.5x | E51.4% | n/a | ||
| ILMNIllumina | US$135.43 | -3.6% | -30.2% | US$21.5b | US$159.73 | PS4.8x | E70.2% | n/a |